Corpus ID: 204854148

High-throughput screening of myxoid liposarcoma cell lines reveals survivin as a potential novel druggable target

  title={High-throughput screening of myxoid liposarcoma cell lines reveals survivin as a potential novel druggable target},
  author={Marieke A. de Graaff and Shruti Malu and Irma Guardiola and Alwine B Kruisselbrink and Yvonne A. de Jong and Willem E Corver and Hans Gelderblom and Patrick Hwu and Torsten O. Nielsen and Alexander J. Lazar and Neeta Somaiah and Judith V.M.G. Bov{\'e}e},
1 Citations
Molecular signatures of tumor progression in myxoid liposarcoma identified by N-glycan mass spectrometry imaging
Findings mirror recent observations in colorectal cancer, breast cancer, ovarian cancer, and cholangiocarcinoma, and are in line with a general role of high-mannose glycans and higher-antennary complex-type glycans in cancer progression. Expand


Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation
The established DL-221 cell line is the only published available myxoid liposarcoma cell line that underwent spontaneous immortalization, without requiring SV40 transformation, and its xenograft model are unique and helpful tools to study the biology and novel potential-targeted treatment approaches. Expand
Targeting survivin as a potential new treatment for chondrosarcoma of bone
Sensitivity to YM155, a survivin inhibitor currently in phase I/II clinical trial for other tumors, showed that especially TP53 mutant cell lines were sensitive, but no caspase 3/7 or PARP cleavage was observed, indicating that survivin is more involved in cell-cycle regulation than in apoptosis. Expand
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
Overall survival was improved in patients assigned to eribulin compared with those assigned to an active control, suggesting that eriboxin could be a treatment option for advanced soft-tissue sarcoma. Expand
HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo
It is concluded that complex formation between RET and other RTKs may cause RTK inhibitor resistance and HSP90 inhibitors can overcome this resistance and are thus promising drugs for treatment of MLS/RCLS. Expand
Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib
The combination of KIT inhibition with IAP antagonists in GIST helps to cure GIST as a subset of GIST cells evade apoptosis and eventually develop resistance to drug-induced apoptosis. Expand
Regulatory mechanisms, expression levels and proliferation effects of the FUS–DDIT3 fusion oncogene in liposarcoma
It is concluded that FUS–DDIT3 is uniquely regulated at the transcriptional as well as the post‐translational level and that its expression level is important for MLS tumour development. Expand
Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic Strategies
In this review, recent progress in understanding the molecular basis of survivin is discussed and therapeutic strategies targeting survivin in preclinical studies are briefly summarized. Expand
Survivin inhibitor YM155 suppresses gastric cancer xenograft growth in mice without affecting normal tissues
The results demonstrated that YM155 inhibits cell proliferation, induces cell apoptosis, reduces cancer stem cell expansion, and inhibits xenograft tumor growth in gastric cancer cells, and elucidate a new mechanism by which YM 155 inhibits Gastric cancer growth by inhibition of CSCs. Expand
Targeting of Survivin Pathways by YM155 Inhibits Cell Death and Invasion in Oral Squamous Cell Carcinoma Cells
Evidence is provided showing that YM155 could act as a small molecule survivin inhibitor on survivin-rich expressed SCC9 cells in culture as well as when grown as tumor in a xenograft model and it is suggested that survivin could be further developed as a potential therapeutic agent for the treatment of survivin -rich expressed OSCC. Expand
Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives
Trabectedin is an old new drug with proven potential to impact the lives of patients with soft tissue sarcoma and other solid malignancies and had a similar outcome as doxorubicin when given as a single agent in the first-line setting. Expand